Cetera Investment Advisers Neurocrine Biosciences Inc Transaction History
Cetera Investment Advisers
- $42.2 Billion
- Q2 2024
A detailed history of Cetera Investment Advisers transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cetera Investment Advisers holds 7,112 shares of NBIX stock, worth $869,442. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,112
Previous 6,593
7.87%
Holding current value
$869,442
Previous $909,000
7.7%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.73 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.23 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$563 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$302 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$289 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...